TCGA-EW-A1PG-01A-11R-A144-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 35
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 299613f5-2f9a-4687-ab0c-323bf38f3699 | — | — | 0.899 |
| 2 | TCGA-BH-A201-01A-11R-A14M-07 | — | A | 0.868 |
| 3 | C3L-01838 | — | cohortSQ1 | 0.858 |
| 4 | TCGA-AN-A0AS-01A-11R-A00Z-07 | — | C | 0.857 |
| 5 | ULC1700T_S19 | — | cohortMD2 | 0.852 |
| 6 | TCGA-34-5928-01A-11R-1820-07 | — | cohortSQ1 | 0.842 |
| 7 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.810 |
| 8 | TCGA-BH-A0BO-01A-23R-A12D-07 | — | A | 0.807 |
| 9 | TCGA-A2-A259-01A-11R-A16F-07 | — | A | 0.798 |
| 10 | TCGA-77-A5G1-01A-11R-A27Q-07 | — | cohortSQ1 | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.570 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.490 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.480 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |